On August 25, 2026 AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, reported a new study published in Cell Stem Cell describing a universal, stem cell-derived dendritic cell platform that can be personalized to an individual patient’s tumor and used to train the immune system to attack cancer. The study, "Engineered Human iPSC-Derived Dendritic Cells Dressed with Tumor MHC Complexes as a Cancer Vaccine," was led by senior author Robert Blelloch, M.D., Ph.D., of UC San Francisco (UCSF), and includes AIVITA’s Krystal Godding, Gabriel I. Nistor, M.D., and Hans S. Keirstead, Ph.D. among its authors (Cell Stem Cell).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The UCSF team engineered dendritic cells, the immune system’s primary antigen-presenting cells, from induced pluripotent stem cells (iPSCs) and used gene editing to remove the surface markers that would normally trigger immune rejection, creating an unlimited, "off-the-shelf" cell source. They then "dressed" these universal dendritic cells with the complete antigen signature carried on a patient’s own tumor cells, rather than a single synthetic target. The resulting dressed dendritic cells trained matched patient T cells to recognize and kill tumor cells from both blood cancer (leukemia) and solid tumor samples, and slowed tumor growth in an animal model.
AIVITA’s contribution was central to extending this proof-of-concept from blood cancer into solid tumors. Drawing on de-identified tumor tissue and matched naive peripheral blood mononuclear cells (PBMCs) from ovarian cancer patients enrolled in AIVITA’s own Phase 2 clinical trial (ClinicalTrials.gov NCT00331526), AIVITA’s team grew and supplied the patient-specific tumor cells that gave UCSF’s dressed dendritic cells their antigen target and collaborated with the UCSF team throughout the studies that followed. T cells trained by dendritic cells dressed with this AIVITA-supplied material showed a marked increase in T-cell stimulation and killing of matched ovarian tumor cells, extending validation of the platform beyond blood cancer into solid tumors, the category at the center of AIVITA’s own therapeutic pipeline.
"This study is an important external validation of a scientific thesis AIVITA has pursued since our founding: that a patient’s own tumor holds the most complete and personalized map of the antigens the immune system needs to see," said AIVITA CEO Dr. Hans S. Keirstead. "The UCSF team has built an elegant, scalable way to put that map onto an unlimited supply of lab-grown dendritic cells."
"Our pan-antigenic platform and UCSF’s dressing approach solve the same problem from two different angles: an unlimited, personalized supply of a patient’s true antigen repertoire," said Gabriel I. Nistor, M.D., chief science officer at AIVITA. "We supplied the complete antigen signature of a real tumor rather than a single synthetic peptide, which is why the T-cell response was so strong."
The study was supported by the National Institutes of Health (U01CA244452), the California Institute for Regenerative Medicine (DISC0-13806, EDUC4-12812), a NIH Cancer Moonshot Award, a Sandler Program for Breakthrough Biomedical Research New Frontiers Award, and the Benioff Initiative for Prostate Cancer Research (UCSF News).
(Press release, AIVITA Biomedical, AUG 25, 2026, View Source [SID1234670344])